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Breast cancer remains the first cancer-related cause of death in women worldwide, 
particularly in developing countries in which most cases are diagnosed in late stages. 
Although most cancer studies are based in the genetic or epigenetic changes of the 
tumor cells, immune cells within the tumor stroma often cooperate with cancer pro-
gression. Particularly, monocytes are attracted to the tumor primary site in which they 
are differentiated into tumor-associated macrophages that facilitate tumor cell invasion 
and metastasis. In this study, we used three-dimensional cultures to form acini-like 
structures to analyze the inflammatory secretion profile of tumor cells individually or 
in co-culture with monocytes. Breast cancer cell lines and primary isolates from eight 
Mexican patients with breast cancer were used. We found high levels of RANTES/CCL5, 
MCP-1/CCL2, and G-CSF in the breast cancer individual cultures, supporting an import-
ant recruitment capacity of monocytes, but also of neutrophils. The co-cultures of the 
tumor cells and monocytes were significantly enriched with the potent pro-inflammatory 
cytokines interleukin (IL)-1β and IL-8, known to support malignant progression. We also 
found that the interaction of tumor cells with monocytes promoted high levels of matrix 
metalloproteinases (MMP)-1, MMP-2, and MMP-10. Our study supports that a key event 
for malignant progression is the recruitment of different immune cell populations, which 
help to sustain and enhance a chronic inflammatory microenvironment that highly favors 
tumor malignancy.
Keywords: breast cancer, monocytes, matrigel-based 3D culture, inflammation, il-1β, il-8, MMPs
Abbreviations: BrC, breast cancer; PC, primary cultures; PM, primary monocytes; UIVC-IDC or UIVC-NIDC, Unidad de 
Investigación en Virología y Cáncer- Invasive or Non-invasive ductal carcinoma; MMPs, matrix metalloproteinases; ECM, 
ectracellular matrix; EMT, epithelial-to-mesenchymal transition; TAMs, tumor-associated macrophages; MDSCs, myeloid-
derived suppressor cells; MUC-1, mucin 1 (or epithelial membrane antigen); EpCAM, epithelial cell adhesion molecule.
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inTrODUcTiOn
Breast cancer (BrC) is the most common cancer and the main 
cause of cancer-related death in women worldwide. BrC greatly 
affects the quality of life of working-age women, and the likeli-
hood of patients to present aggressive cancer features, such as 
metastasis, resistance to treatment, and disease relapse, remains 
high, particularly in developing countries in which BrC is diag-
nosed at advanced stages (1). Great efforts have been placed to 
grade BrC into clinical stages to try to improve the effectiveness 
of therapy schemes. However, tumor classification and directed 
therapies are based mainly on the genetic or epigenetic changes 
of the tumor cell itself (2). Today, we understand that tumors are 
formed by a variety of cells of different origins, the tumor stroma 
or tumor microenvironment, in which the tumor cell coexists 
with non-tumor cells, for instance fibroblasts, endothelial cells, 
and immune cells (3, 4). One of the main cell populations found 
in the stroma of many types of tumors are the macrophages, 
termed tumor-associated macrophages or TAMs (5, 6).
Increasing evidence supports that chronic inflammation 
deeply impacts cancer initiation and progression (7). Circulating 
monocytes are persistently chemoattracted to inflammatory 
sites in which they differentiate into macrophages that help to 
maintain the inflammatory process, thus creating a positive 
loop. Macrophages were initially thought to exclusively per-
form immune defense functions, such as removal of invading 
pathogens and cancer cells, because of their potent phagocytic, 
oxygen-dependent intracellular killing and antigen-presenting 
activities. However, macrophages also participate in clearing of 
aging cells and tissue remodeling in non-pathological conditions 
and healing or tissue repair after pathological conditions. To do 
this, macrophages are highly plastic cells of which there are many 
subtypes expressing different sets of bioactive molecules that con-
tribute to tissue growth through mechanisms of cell proliferation, 
angiogenesis, and immunosuppression (8–10). Since the pioneer-
ing studies by Lin et al. using murine BrC models, it was clear that 
preventing the arrival of monocytes into the tumor site resulted in 
small tumors and decreased metastases (11). Today, there is evi-
dence supporting that TAMs have crucial roles in angiogenesis, 
invasion, and metastasis, and a dense infiltration of these cells 
into human primary tumors is significantly associated with poor 
prognosis (12, 13). Both inflammatory and anti-inflammatory 
macrophages can potentially cooperate with tumor evolution.
To study the communication that tumor cells establish with 
monocytes, we have previously used aggressive (MDA-MB-231) 
and non-aggressive (MCF-7) BrC cell lines co-cultured with the 
monocytic cell line U937 in a Matrigel-based three-dimensional 
(3D) system, finding that U937 cells significantly upregulate 
expression of matrix metalloproteinases (MMPs) and inflam-
matory mediators in response to soluble factors from the 
most aggressive BrC cells (14). To follow up those findings, we 
decided to test primary tumor cells obtained from BrC patients 
and analyze their secretion profiles, both individually and in 
co-culture with primary monocytes (PM) and monocytic cell 
lines. We think that working with primary isolates we would 
obtain information that more closely reflected the biology of the 
tumors. We found that primary BrC cells are secreting high levels 
of the chemokines RANTES/CCL5, MCP-1/CCL2, and G-CSF, 
which revealed their potential capability to recruit and activate 
monocytes. When BrC cells were co-cultured with monocytes, 
we observed a significant increased secretion of interleukin (IL)-
1β and IL-8, two interleukins associated with malignant progres-
sion of several types of cancer. Interestingly, IL-1β and IL-8 also 
distinguished co-cultures of aggressive from non-aggressive BrC 
cell lines. Finally, we also observed increased levels of MMP-1, 
MMP-2, and MMP-10 in co-cultures. This study supports the 
idea that the potential of aggressiveness of BrC cells is given by 
their ability to recruit monocytes and to instruct them to secrete 
high levels of potent pro-inflammatory cytokines IL-1β and IL-8, 
and metalloproteinases MMP-1, MMP-2, and MMP-10. These 
mechanisms may favor tumor progression contributing with 
recruitment of other immune cells and facilitating cell invasion 
and metastasis.
MaTerials anD MeThODs
Patient recruitment and Primary cell 
isolation
Patient samples were obtained from the tissue bank of the Unidad 
de Investigación en Virología y Cáncer, Hospital Infantil de 
México Federico Gómez, for which patients signed an informed 
consent, and the protocol was approved by the Scientific, Ethics, 
and Biosafety Institutional Review Boards. Tumor samples were 
taken from patients diagnosed with ductal carcinoma and with 
no previous neoadjuvant therapy before tissue resection.
The tumor tissue was rinsed with PBS and mechanically 
disaggregated with a scalpel in 1–2 mm fragments, which were 
subsequently digested for 2 h at room temperature (RT) with a 
mixture of 1 mg/mL collagenase type I and 100 U/mL hyaluro-
nidase (both from Sigma; Saint Louis, MO, USA) in DMEM/F12 
containing 100 U/mL penicillin and 100 μg/mL streptomycin, in 
constant stirring. The resulting suspension was filtered through 
a wide pore membrane and subsequently in a 100  μm pore 
membrane. The cells were pelleted and washed twice with sterile 
PBS and finally placed in their culture media. Cell morphology 
of primary isolates was analyzed and compared to the morphol-
ogy of the commercial BrC cell lines in 2D (monolayer) and 3D 
culture conditions. Images were taken with an Olympus BX-41 
microscope (Olympus Corporation, Tokyo, Japan). Primary cul-
tures (PC) were given consecutive numbers; of 16 tumor tissues 
plated, eight PC were established for at least seven passages. These 
cultures were named UIVC-IDC-1, -4, -5, -6, -9, -10, -11, and 
UIVC-NIDC-1.
cell culture
All commercial cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and culture media 
and supplements from Gibco Invitrogen Cell Culture (Carlsbad, 
CA, USA) unless specified differently. The human monocytic 
cell lines THP-1 (No. TIB-202), U937 (No. CRL-1593.2), and the 
BrC line T47D (HTB-133) were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (FBS), 100  U/mL 
penicillin, and 100 U/mL streptomycin, at 37°C in 5% CO2. BrC 
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cells MCF-7 (No. HTB-22) and MDA-MB-231 (No. HTB-26) 
were cultured in DMEM/F12 medium supplemented with 10% 
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C 
in 5% CO2. BrC cells HS578T (No. HTB-126) were cultured in 
high glucose (4.5 g/L) DMEM medium supplemented with 10% 
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C 
in 5% CO2. MCF-10A cells (No. CRL-10317) were cultured in 
DMEM/F-12 medium supplemented with 20 ng/mL of epidermal 
growth factor (EGF; PeproTech, Rocky Hill, NJ, USA), 10 μg/mL 
insulin, 0.5 μg/mL hydrocortisone, 100 ng/mL cholera toxin (all 
from Sigma Chemical Co., St. Louis, MO, USA), 5% horse serum, 
100 U/mL penicillin, and 100 μg/mL streptomycin. Primary tumor 
cell isolates were cultured in DMEM/F12 supplemented with 5% 
horse serum, 100 U/mL penicillin and 100 μg/mL streptomycin, 
100 ng/mL cholera toxin, 0.5 μg/mL hydrocortisone, 10 μg/mL 
insulin, and 20 ng/mL of EGF at 37°C in 5% CO2 atmosphere.
isolation of Peripheral Blood PM
Peripheral blood mononuclear cells (PBMCs) were isolated 
according to the following protocol: 40 mL of blood of healthy 
volunteers was extracted, diluted in a 1:3 proportion with sterile 
endotoxin-free PBS (Gibco Invitrogen Cell Culture), and sub-
jected to density gradient centrifugation with Histopaque®-1077 
(Sigma-Aldrich Inc., St. Louis, MO, USA) per 30  min at 
2,000 rpm. PBMCs were then carefully retrieved from the gra-
dient and washed three times with PBS, each time followed by 
slower centrifugation (1,500, 1,250, and 1,000 rpm). To obtain the 
monocyte-enriched fraction, PBMCs were subjected to negative 
selection with the Monocyte Isolation Kit II Human (Miltenyi 
Biotec Inc., Auburn, CA, USA) following the manufacturer’s rec-
ommendations as we briefly describe next. PBMCs were washed 
once with diluted 1:20 MACS BSA Stock Solution (Miltenyi 
Biotec Inc., Auburn, CA, USA), counted, and adjusted to a 
density of 107 cells per 30 μL of buffered solution; 10 μL of FcR-
blocking reagent and 10 μL of monocyte biotin-antibody cocktail 
were then added for every 107 cells to be labeled; cells were mixed 
and incubated for 15 min at 4°C. An additional 30 μL of buffered 
solution was added plus 20 μL of anti-biotin microbeads for every 
107 cells to be labeled; cells were mixed and incubated for 20 min 
at 4°C. Cells were then washed once with buffered solution, 
centrifuged at 1,500 rpm for 5 min, and resuspended in 1.5 mL 
of buffered solution for magnetic separation. Suspension of cells 
was passed through a pre-rinsed LS column (Miltenyi Biotec Inc., 
Auburn, CA, USA) and 7  mL of buffered solution was added. 
The monocyte-enriched cells were collected in a conical 15 mL 
tube, counted, and if not cultured immediately, monocytes were 
frozen at a density of 2 × 106 in 1 mL of DMEM/F12 medium 
supplemented with 50% FBS and 10% DMSO at −80°C. PM used 
for experimentation were never frozen for more than 2 months 
after isolation. Cultures were maintained in DMEM/F12 medium 
supplemented with 6% FBS, 100 U/mL penicillin, and 100 μg/mL 
streptomycin, at 37°C in 5% CO2 atmosphere. Each set of experi-
ments was performed utilizing PM of at least two different donors 
(each donor isolates independently because pooling resulted in 
monocyte activation). The phenotype of purified monocytes was 
very homogeneous between different isolates: CD34neg CD11bpos 
CD14pos CD64pos CD68neg CD16neg, and also with both monocytic 
cell lines, which corresponds to the phenotype of a non-activated 
immature monocyte (15).
immunocytochemistry of epithelial 
Markers
A total of 20,000 cells of the primary isolates were plated on 8-well 
chamber slides (Nunc® Lab-Tek® Chamber Slide System, Sigma), 
cultured for 48 h in their correspondent media, rinsed with PBS, 
and fixed with paraformaldehyde at RT for 10 min. Cells were then 
hydrated with PBS and permeabilized with 0.05% triton X-100 
for 10 min at 4°C. Endogenous peroxidase activity was blocked 
by incubating the slides in peroxidase blocking solution (Dako, 
Inc., Carpinteria, CA, USA). Non-specific antibody binding was 
blocked by incubation with 8% albumin in PBS for 20 min. The 
slides were incubated with the following primary antibodies at an 
optimized concentration: mouse monoclonal anti-human anti-
PanCytokeratin (Clone AE1/AE3; Biocare Medical; Concord, 
CA, USA), mouse monoclonal anti-human anti-mucin 1 (MUC-
1) [epithelial membrane antigen (EMA; Clone Mc-5; Biocare 
Medical)], and mouse monoclonal anti-human anti-epithelial 
cell adhesion molecule (EpCAM, clone AUA1; Biocare Medical). 
Cells were incubated overnight in a moist chamber at 4°C. The 
EnVision Detection Kit (Dako; Carpinteria, CA, USA) was 
employed as the detection system. Cells were counterstained 
with hematoxilin for 5 min followed by 5 min 0.9% ammonium 
hydroxide at RT, rinsed with distilled water, and left to dry at 
RT and permanently cover slipped. Slides were analyzed and 
photographed with an Olympus BX-41 microscope (Olympus 
Corporation, Tokyo, Japan).
Primary culture growth in Medium  
of Mesenchymal cell
4 × 105 cells from primary isolates were seeded in 4 mL of low 
glucose (1 g/L) DMEM medium (Gibco Invitrogen), with sodium 
pyruvate 110 mg/L, without HEPES and supplemented with 15% 
FBS, 1% l-glutamine, and 100  U/mL penicillin and 100  μg/
mL streptomycin and incubated at 37°C in 5% CO2. Cells were 
maintained for 5–7  days in the described conditions and their 
growth evaluated. Results were scored as none when no growth 
was observed, one cross when cells attached and formed ≈40% 
of a confluent layer, two crosses 80–90% of confluence, and three 
crosses when cells were passaged and proliferate in a new culture 
flask with mesenchymal cell medium. Bone marrow mesenchy-
mal cells were used as positive control and MCF-10A cells as 
negative control.
3D culture and harvest of cell culture 
supernatants
For 3D individual cultures, a 40 μL base of Matrigel was added 
per well of an 8-well chamber slide system (8-well plates, Lab-Tek 
Chamber Slide System, Nalgene Nunc International, Rochester, 
NY, USA), incubated for 30 min at 37°C and 800 cells were added 
in 400 μl of the correspondent culture medium supplemented 
with 4  ng/mL of EGF and 2% Matrigel. For 3D co-cultures, 
4 ×  105 monocytes contained in 1  mL of their correspondent 
medium supplemented with 2% Matrigel and 2% FBS for U937 
4Espinoza-Sánchez et al. Tumor Cell–Monocyte Communication
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 205
and THP-1 monocytes, or 2% Matrigel and 6% FBS for PM, 
were plated per well of a 24-well flat-bottom culture plate. A 
transwell cell culture insert with pore size of 0.4 μm (Thermo 
Fisher Scientific™ NuncTM; Waltham, MA, USA) was placed in 
each well containing 1  mL of a 4 ×  105 BrC cells in their cor-
respondent medium supplemented with 2% Matrigel and 2% FBS 
(for commercial cell lines) or 5% horse serum for PC. Controls 
of individual cell cultures with the same media were included. 
After 5 days of culture, the supernatants from bottoms and tops 
of the 3D co-cultures were recovered, mixed, aliquoted, and kept 
at −20°C until use.
analysis of cytokine Profiles
The following analytes were determined in the supernatants of the 
cultures: granulocyte-colony-stimulating factor (G-CSF), granu-
locyte-macrophage-colony-stimulating factor (GM-CSF), inter-
leukin (IL)-1 beta (IL-1β), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, 
IL-17, interferon-alpha 2 (INF-α2), monocyte chemoattractant 
protein-1 (MCP-1) also known as chemokine CCL2, regulated on 
activation normal T cell expressed and secreted (RANTES) also 
known as chemokine CCL5, EGF, vascular endothelial growth 
factor (VEGF), and a panel of the MMP-1, -2, -7, -9, and -10. The 
determinations were done with the multiplexing assay platform 
from MILLIPLEX (EMD Millipore Corporation, Billerica, MA, 
USA) following the manufacturer’s recommended procedure. 
Briefly, in each well of a 96-well flat-bottom culture plate 25 μL 
of assay buffer was mixed with 25 μL of supernatants or controls 
and 25 μL of the detection microbeads cocktail. The mixture was 
incubated at 4°C overnight with orbital agitation. Wells were 
then washed twice with washing buffer, 25 μL of the detection 
antibodies mix was added to each well, and the plate was incu-
bated at RT with orbital agitation for 1 h. After incubation, 25 μL 
of streptavidin-phycoerythrin was added to each well followed 
by 30 more minutes of incubation at RT with orbital agitation. 
The wells were then washed twice with washing buffer, 150 μL 
of PBS was added to each well to proceed with the analysis in 
Luminex MAGPIX multiplexing instrument, and the analysis of 
data was performed in the xPONENT® Software. Three biological 
replicates were analyzed.
Migration and invasion assays
Migration assays with U937, THP-1, and fresh PM were 
performed in 24-well plates using polycarbonate membrane 
transwell inserts with 8-μm pores (Corning Costar, USA) filled 
with Matrigel. 1.5 × 105 monocytes were resuspended in 200 μL 
of RPMI without serum and placed in the upper chamber. Then, 
transwells were placed in a 24-well culture dish containing 800 μL 
of RPMI without serum but supplemented with either 100 ng/
mL of GM-CSF, MCP-1, or RANTES (all from PeproTech, Rocky 
Hill, NJ, USA) that was used as chemoattractant. Cell migration 
was allowed to progress for 24 h at 37°C in a humidified 5% CO2 
environment. The migrating cells were counted at 2, 4, 6, and 24 h 
using a microscope Motic AE31, and images were acquired with a 
digital camera (Moticam 5.0 MP). The mean cell count from three 
random fields (at 100× magnification) was used for the analysis. 
For the BrC cell lines invasion assays, a total of 6 × 105 cells were 
resuspended in 200 μL of their respective media without sera 
and placed in the upper chamber of the Transwell filled with 
Matrigel (as for the monocytes). The Transwells were placed in a 
24-well culture dish containing 800 μL of their respective media 
with sera or without sera but supplemented with 100 ng/mL of 
IL-8 as chemoattractant (PeproTech, Rocky Hill, NJ, USA). The 
experiment proceeded as for monocytes and after 48 h, invad-
ing cells were stained with crystal violet and observed under 
the microscope. The mean cell count from three random fields 
(at 100× magnification) was used for the analysis of Figure 6C 
and the integrated optical density (IOD) for the analysis of Figure 
S1 in Supplementary Material. Three biological replicates were 
performed.
immunofluorescence assay
3 × 104 cells of each of the cell lines were seeded on coverslips 
for 24  h in their respective media. Then, cells were fixed with 
4% paraformaldehyde for 10 min, and permeabilized with 0.2% 
Triton X-100 in PBS for 20 min. Cells were blocked with blocking 
buffer (10% goat serum, 1% BSA, 0.2% triton X-100, and PBS 
1X) for 1 h and then stained with the primary antibodies: mouse 
monoclonal anti-E-Cadherin antibody (Clone: 36/E-cadherin; 
BD Biosciences, San José, CA, USA), rabbit monoclonal anti-
Vimentin antibody-Alexa Fluor-594 (Clone: EPR3776; Abcam, 
Cambridge, MA, USA), overnight at 4°C. After that, cells were 
incubated with the secondary antibody goat anti-mouse-IgG-
FITC antibody (Sigma-Aldrich Co., St. Louis, MO, USA) for 
30 min. Nuclei were stained with DAPI for 25 min. Cells were 
observed using a fluorescence microscope Olympus BX51, and 
images were acquired with a digital camera (Camedia C4040, 
Olympus).
statistical analysis
Statistical comparison of values from the different conditions 
tested was performed with the GraphPad Prism 5 Software, using 
Kruskal–Wallis test and Mann–Whitney test to compare all data 
columns. Statistical significance (p) ≤0.05 was indicated with *, 
≤0.01 was indicated with **, and ≤0.001 with ***.
resUlTs
aggressive Breast cancer cells establish 
a Microenvironment enriched with il-1β 
and il-8
We have previously generated evidence that aggressive BrC cells 
modulate the expression of monocytes to favor conditions for 
tumor invasion (14). We define the aggressive potential of BrC 
cells as follows: to present a cancer stem cell-like phenotype 
CD44+ CD24−/low; to present the epithelial-to-mesenchymal tran-
sition (EMT), which is characterized by positivity to vimentin 
(mesenchymal marker) and negativity to E-cadherin (epithelial 
marker), and to be invasive in transwell assays. According to these 
characteristics, MCF-7 and T47D cells were classified as non-
aggressive and MDA-MB-231 and HS578T cells as aggressive. 
This characterization correlates with the ability of MDA-MB-231 
and HS578T cells, but no of MCF-7 and T47D cells, to form 
metastasis in immunodeficient mice (16–19). To extend our 
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initial observations, we used three different types of monocytes: 
commercial U937 and THP1 monocytes, which were obtained 
from patients with diffuse histiocytic lymphomas and have been 
widely used as models of macrophage differentiation (20–23), 
and PM isolated from healthy donors. All the different monocytes 
presented an immature non-activated phenotype (15).
The co-cultures with the commercial BrC cell lines and mono-
cytes were done in a Matrigel 3D matrix, after which the content 
of several cytokines, chemokines, and growth factors (G-CSF, 
GM-CSF, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17, 
INF-α2, MCP-1, RANTES, EGF, and VEGF) were measured 
in the supernatants. Consistent readings were obtained for the 
following analytes: RANTES, MCP-1, G-CSF, GM-CSF, IL-8, 
IL-1β, INFα2, and IL12p70, all related to inflammatory processes, 
although only the first six have been previously associated with 
pro-tumor effects. Figure 1A shows three independent assays of 
the three types of monocytes in co-culture with the commercial 
BrC cells. It can be observed that IL-1β and IL-8 levels were 
increased upon co-culture, while the opposite happened with 
INF-α2 and IL-12p70, which presented the highest levels in some 
of the monocytes cultured individually. The most relevant result 
observed was that of IL-1β and IL-8 (Figure 1B). In the case of 
IL-1β, we found statistical differences between co-cultures and 
individual cultures. Interestingly, the concentration of IL-1β also 
allowed distinguishing between co-cultures of the most aggressive 
BrC cells (average of 183.7 pg/mL) and the non-aggressive cells 
(94.0 pg/mL). Similarly, IL-8 basal levels (3D) perfectly segregate 
non-aggressive (average of 30.83 pg/mL) from aggressive tumor 
cells (average of 9,654 pg/mL). Also, the levels of IL-8 increased 
significantly when non-aggressive tumor cells were co-cultured 
with monocytes (average of 6,737 pg/mL), although we did not 
observe a significant difference between co-cultures of the BrC 
aggressive cells and co-cultures of the non-aggressive cells.
clinical characteristics of Breast cancer 
Patients and Morphology of cell isolates 
in culture
To extend these observations, the experiments were repeated 
using primary tumor cells isolated from BrC Mexican patients. 
The tumor cells were derived from eight female patients with an 
average age of 56.8  years (range 42–75). All tumors were clas-
sified as ductal, with seven out of eight already showing tissue 
infiltration and three patients already presenting lymph node 
involvement. Seven tumors were classified as histological grade 
II and one as grade III, and seven were clinical stages IIA or IIB 
and one stage I (Table 1).
For the duration of this study, PC were maintained for up 
to seven passages in mammary epithelial cell growth medium. 
We determined their identity as epithelial cells after positive 
staining to three well known epithelial markers: a panel of 
cytokeratins, mucin 1, and EpCAM (Figure  2A; Table  2). The 
primary tumor cells expanded in epithelial cell growth medium 
were also plated in medium specialized to grow mesenchymal 
cells, we thought that this was important to exclude the possibility 
of culture contamination with other resident cells of the tumor 
stroma that could have pro-tumoral activities. We found that 
cultures UIVC-IDC-1, -4, -6 and UIVC-NIDC-1 proliferated to 
different extents in mesenchymal medium (Figure 2B; Table 2). 
However, cells recovered after expansion in this medium still 
were positive for epithelial markers (Figure 2C). We concluded 
that cells expanding in this medium were not mesenchymal cells 
contaminating the primary isolates, but rather that these tumor 
epithelial cells acquired mesenchymal characteristics that allowed 
them to adapt to mesenchymal culture conditions. MCF-10A 
non-transformed cells were unable to expand in mesenchymal 
medium (not shown).
We assessed the morphology of cells in monolayer (2D) 
according to the capacity to form cobblestone or spindle-like 
shapes (Figure 3A; Table 2). Only culture UIVC-IDC-5, -10 and 
UIVC-NIDC-1 formed an organized monolayer with polygonal-
shaped cells and well-delimited cell-to-cell interactions. Cells 
from the rest of the cultures had an elongated shape, formed less 
organized monolayers and in some regions cells stacked randomly 
on top of each other, a characteristic of cells that have lost contact 
inhibition. We also compared the 3D colonies of the primary iso-
lates with the ones formed by MCF-10A, and the non-aggressive 
and aggressive cell lines. MCF-10A non-transformed cells form 
well-organized spherical structures in which cells are polarized 
with the basal side facing the extracellular matrix (ECM) and 
the basolateral side facing the hollow lumen of the sphere. Only 
cultures UIVC-IDC-5 and -11 formed medium size structures 
resembling spheres, cultures UIVC-IDC-6, -9, and -10 formed 
smaller structures and cultures UIVC-IDC-1, UIVC-IDC-4, and 
UIVC-NIDC-1 did not organized in any kind of recognizable 
sphere-like shape (Figure 3B; Table 2). Based on the 2D and 3D 
morphology, we conclude that the primary isolates more closely 
resemble the highly aggressive BrC cells, which is in contrast with 
most of the patients’ clinical profiles.
co-cultures of Primary Breast cancer 
isolates and Monocytes are also enriched 
with il-1β and il-8
We co-cultured the primary BrC isolates with the PM. The results 
showed that MCP-1, G-CSF, RANTES, GM-CSF, INF-α2, and 
IL12-p70 analytes gave no differences between the 3D individual 
cultures and the 3D co-cultures (data not shown). However, 
IL-1β and IL-8, which in commercial lines allowed to distinguish 
between aggressive and non-aggressive BrC cells, showed again 
a significant increased concentration in co-culture (Figure  4). 
IL-1β increased from 3.3  pg/mL (individual 3D culture) to 
16.5 pg/mL (co-culture), while IL-8 increased from 8,886.3 pg/
mL (3D) to 12,027.4 pg/mL (CC).
MMP-1, MMP-2, and MMP-10 are induced 
in Breast cancer Primary cells/Monocytes 
co-cultures
Our initial findings also support that aggressive MDA-MB-231 
cells promote secretion of MMPs in co-culture with U937 
monocytes (14). To extend those results, we analyzed the levels 
of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 present in 
the primary isolates individually cultured or co-cultured with 
PM. We did not find significant differences in the secretion levels 
FigUre 1 | levels of inflammatory cytokines present in supernatants of commercial breast cancer (Brc) cell lines in co-culture with monocytes. 
Inflammatory cytokines were determined in three-dimensional (3D) individual cultures of the BrC cell lines (indicated as 3D) and in co-culture with the three different 
sources of monocytes independently [THP-1, U937, and primary monocytes (PM); indicated as cells co-cultured (CC)]. (a) The means and SD of three independent 
co-culture experiments are shown (in picogram/milliliter). (B) Summary of the cytokines that gave statistically significant differences. For the statistical analysis, 
MCF-7 and T47D cells were grouped as non-aggressive BrC cells and MDA-MB-231 and HS578T were grouped as aggressive BrC cells. THP-1, U937, and PM 
were grouped as Monocytes, and statistics were calculated using all combinations of aggressive vs non-aggressive BrC cells with all the types of monocytes. Left 
panel [interleukin (IL)-1β]: statistical differences were found between BrC cells cultured individually vs in co-culture with monocytes, and between co-cultures of the 
non-aggressive BrC cells vs the co-cultures of the aggressive cells. Right panel (IL-8): statistical differences were found between non-aggressive cells cultured 
individually (3D) and the rest of the groups: non-aggressive CC with monocytes and with aggressive cells either cultured individually or in co-culture with monocytes. 
Statistical significance p ≤ 0.05 was indicated with *, p ≤ 0.01 with **, and p ≤ 0.001 with ***. The statistical tests comparing monocytes against co-cultures 
showed significant differences only for HA-BrC (IL-1β p ≤ 0.0001 and IL-8 p = 0.0014) but not for NA-BrC cells (IL-1β p = 0.752 and IL-8 p = 0.0942).
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of MMP-7 and MMP-9 (data not shown). Supernatants obtained 
from the primary isolates UIVC-IDC-1, UIVC-IDC-4, UIVC-
IDC-6, and UIVC-NIDC-1 did not show detectable levels of 
MMP-7 and MMP-9. Primary culture UIVC-IDC-11 secreted the 
highest basal level of MMP-7 with 297,006 and 339,296 pg/mL 
in its correspondent co-culture. UIVC-IDC-11 was also the 
TaBle 1 | clinical characteristics of breast cancer patients.
Primary culture age histological 
subtype
histological 
grade
TnM 
staging
clinical 
stage
UIVC-IDC-1 52 IDC 2 T1N0M0 I
UIVC-IDC-4 63 IDC 2 T1N1M0 IIA
UIVC-IDC-5 75 IDC 2 T2N0M0 IIA
UIVC-IDC-6 55 IDC 2 T1N0M0 IIA
UIVC-NIDC-1 56 DCIS 2 T1N0M0 IIA
UIVC-IDC-9 42 IDC 2 T2N1M0 IIB
UIVC-IDC-10 64 IDC 3 T3N0M0 IIB
UIVC-IDC-11 48 IDC 2 T2N1M0 IIB
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ.
FigUre 2 | epithelial markers in breast cancer primary cell cultures. (a) Representative images of epithelial markers (PanCytokeratin, Muc-1/epithelial 
membrane antigen, and EpCAM) in three primary cultures (PC) determined by immunocytochemistry. Non-transformed MCF-10A breast epithelial cells were used as 
positive and U937 monocytes as negative staining controls. (B) Representative images of PC UIVC-IDC-1, -4, and -6 proliferating in mesenchymal medium 
(magnification 100×). (c) Epithelial markers determined by immunocytochemistry in UIVC-IDC-6 after one passage in mesenchymal medium. Scale bars correspond 
to 100 μm, magnification 200×.
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only primary isolate secreting detectable levels of MMP-9. More 
interestingly, MMP-1, MMP-2, and MMP-10 showed significant 
differences between co-cultures and individual 3D cultures 
(Figure 5). In the case of MMP-1 and -2, the basal levels in indi-
vidual cultures were average of 19,264 pg/mL (MMP-1) and of 
12,474 pg/mL (MMP-2), which in co-culture with monocytes was 
further increased 3- and 1.9-fold, respectively. For MMP-10, the 
average level found in supernatants from individual cultures was 
of 219.3 pg/mL and in the co-cultures with monocytes increased 
2.6-fold.
Primary Breast cancer cultures exhibit  
an inflammatory secretion Profile rich  
in chemotactic cytokines
In an attempt to understand the cytokine profile of tumor cells that 
promote an immunological shift or immunoediting in monocytes 
(24), we analyzed the basal expression levels of the commercial 
and primary BrC cells (Figure  6A). We found an interesting 
inflammatory profile promoted by the PC, which consisted of high 
concentrations of MCP-1/CCL2 (average of 9,277.09  pg/mL), 
G-CSF/SDF3 (average of 3,999.37 pg/mL) and RANTES (aver-
age of 953.19  pg/mL) and, lower levels of INF-α2 (average of 
27.07  pg/mL) and IL-12p70 (average of 6.415  pg/mL). For 
GM-CSF, two cultures were polarized from the rest, UIVC-IDC-1 
had 5,022.8 pg/mL and UIVC-IDC-9 had 573.6 pg/mL, the rest of 
TaBle 2 | characterization of breast cancer primary cultures.
Primary culture epithelial 
markers
Proliferation in epithelial 
medium
Proliferation in mesenchymal 
medium
growth (2D) growth 
three-dimensional
eMT invasion
UIVC-IDC-1 Pos Pos ++ Aggressive Aggressive ND ND
UIVC-IDC-4 Pos Pos ++ Aggressive Aggressive ND ND
UIVC-IDC-5 Pos Pos None Non-aggressive Aggressive ND ND
UIVC-IDC-6 Pos Pos +++ Aggressive Aggressive Pos Pos
UIVC-NIDC-1 Pos Pos + Non-aggressive Aggressive Pos Pos
UIVC-IDC-9 Pos Pos None Aggressive Aggressive Pos Pos
UIVC-IDC-10 Pos Pos None Non-aggressive Aggressive Pos Pos
UIVC-IDC-11 Pos Pos None Aggressive Aggressive ND ND
EMT, epithelial to mesenchymal transition; ND, non-determinated; Pos, positive.
FigUre 3 | 2D and three-dimensional (3D) growth of breast cancer (Brc) primary cultures (Pc). (a) MCF-7 and T47D cobblestone-like growth was used 
as representative of cells with non-aggressive features, while MDA-MB-231 and HS578T spindle-like growth was used as representative of aggressive BrC cells. 
MCF-10A cells are included as the type of growth observed with non-transformed cells. Representative images of PC UIVC-IDC-5, UIVC-NIDC-1, and UIVC-IDC-10 
in early passages, which displayed a very similar morphology to non-aggressive BrC cells, while the rest of the primary isolates showed a 2D morphology closer to 
the one found in aggressive cells. Scale bars correspond to 100 μm, magnification 200×. (B) Comparison of the 3D growth of primary isolates with commercial 
non-transformed, aggressive, or non-aggressive cell lines. Scale bars correspond to 50 μm, magnification 200×.
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the primary isolates ranged from 4.5 to 51.2 pg/mL. Interestingly, 
this profile is in good correlation with the profile found in the 
commercial BrC cell lines, with aggressive cells exhibiting higher 
levels of MCP-1 and G-CSF, and GM-CSF appreciably separating 
aggressive from non-aggressive cells. On the contrary, primary 
and commercial BrC cells showed low levels of INF-α2 and 
IL-12p70 (Figure 6A). Other cytokines were either or both, not 
significantly different between aggressive and non-aggressive 
cells or they had no detectable levels, such as IL-2 and IL-4 (data 
not shown).
An important observation taken from this experiment was 
that the most enriched cytokines are critical monocyte chemoat-
tractants. Because of the increased secretion of MMPs, migration 
assays were performed with commercial and PM in response 
to GM-CSF, MCP-1, and RANTES in Matrigel filled Transwell 
inserts. We observed that U937 and THP-1 cells were capable to 
migrate in response to GM-CSF (average numbers of migrating 
cells/field were 115 for U937 and 11.5 for THP-1) and to MCP-1 
(average numbers of migrating cells/field were 99.7 for U937 
and 12.8 for THP-1) and low to null response to RANTES. PM 
FigUre 5 | Matrix metalloproteinases (MMP)-1, MMP-2, and MMP-10 are induced in breast cancer (Brc) primary cell/monocytes co-cultures. 
Concentrations of MMP-1, MMP-2, and MMP-10 measured in supernatants significantly increased when primary cells derived from the eight BrC patients were 
co-cultured with the primary monocytes from healthy donors. Three independent experiments were carried out, and each point represents the mean of all 
determinations for each BrC primary isolate. Statistical significance (p ≤ 0.05) is indicated with *.
FigUre 4 | levels of interleukin (il)-1β and il-8 increased when primary breast cancer (Brc) cells were co-cultured with monocytes. Levels of IL-1β 
(left panel) and IL-8 (right panel) significantly increased when primary cells derived from the eight BrC patients were co-cultured with the primary monocytes from 
healthy donors. Three independent experiments were carried out and each point represents the mean of all determinations for each BrC primary isolate. Statistical 
significance p ≤ 0.05 is indicated with * and p ≤ 0.01 with **.
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showed high basal migratory properties, giving potent responses 
to MCP-1 (average number of migrating cells/field of 54,666.7). 
Although, we observed migration in response to GM-CSF and 
RANTES the number of migrating cells was not different than 
the control without chemoattractant (Figure  6B). U937 cells 
also exhibited migratory properties in the absence of chemoat-
tractant (average number of migrating cells/field 10.7), although 
lesser than PM (18,666.7 cells). On the contrary, THP-1 cells were 
not intrinsically migratory in our experimental conditions even 
without Matrigel. 
Interleukin-8 is another potent chemokine. Since IL-8 and 
MMPs are enriched upon co-culturing of the monocytes and the 
BrC cell lines, we decided to test whether IL-8 could facilitate 
invasion of the tumor cells. Figure 6C shows that the aggressive 
BrC cell lines responded to IL-8 (average number of invading 
cells/field were 11.5 for HS578T and 20.5 for MDA-MB-231 
cells). We did not observe invasive properties in the absence of 
IL-8 or with the non-aggressive cell lines (Figure  6C). These 
data argue that the pro-inflammatory profile of the most aggres-
sive BrC cells serve them to attract monocytes, and the BrC-
monocyte association further enhances the tumor cell invasive 
properties.
DiscUssiOn
Accurate prognosis and treatment of BrC remains a challenge, 
partly because most existing classifications of BrC are based 
on the tumor cell itself, and do not consider all the cell-to-cell 
interactions within the tumor stroma. In particular, TAMs are 
considered to be critical for tumor progression. A high density of 
TAMs indicates a poor prognosis (25–27). To better understand 
how the tumor cell communicates with recruited monocytes, 
we have co-cultivated early passages of BrC primary cell isolates 
and monocytes in a 3D system that recreates the cellular interac-
tions with the ECM. We observed constitutively elevated levels 
of cytokines MCP-1, G-CSF, and RANTES in tumor cells, and 
of IL-1β, IL-8, MMP-1, MMP-2, and MMP-10 after co-culture. 
MCP-1 and G-CSF were potent chemoattractants of monocytes, 
while IL-8 was a potent inducer of invasion of the aggressive BrC 
cells (see Figure 7 for a depiction of a working model).
These cytokines are known to contribute toward the estab-
lishment of the tumor microenvironment. MCP-1, G-CSF, and 
RANTES are powerfull chemoattractants of monocytes and of 
other immune cells, particularly RANTES is a chemoattractant 
of neutrophils. MCP-1 also acts as an autocrine growth factor 
FigUre 6 | Primary breast cancer (Brc) cells basal levels of secretion of inflammatory cytokines. (a) The levels of the cytokines, chemokines, and growth 
factors of interest were determined in the supernatants of the 3D cultures of BrC primary isolates. Each point represents the mean of three determinations made for 
three independent cultures. The horizontal line represents the average of the primary cultures readings. (B) Comparison of the migratory properties of monocytes in 
response to GM-CSF, MCP-1, and RANTES. (c) Invasion assay with the commercial BrC cell lines in response to IL-8. Three independent experiments were 
performed. Statistical significance is indicated by ***p < 0.001 and **p < 0.01.
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for neoplastic cells; promoting angiogenesis, invasion, and metas-
tasis, contributing to tumor growth and dissemination (28, 29). 
Both MCP-1 and RANTES have minimal expression in non-
cancerous epithelial cells and increased expression in neoplastic 
cells. They contribute toward the establishment of an inflamma-
tory microenvironment, which is paradoxically a potent suppres-
sor of the cytotoxic T cell activity. MCP-1 and RANTES are direct 
inhibitors of cytotoxic T cells; and G-CSF is in addition associated 
with the recruitment of myeloid-derived suppressor cells (30, 31). 
IL-8 and IL-1β are also pro-inflammatory cytokines. IL-1β is 
produced primarily by activated macrophages and is involved 
in cell proliferation, differentiation, apoptosis, angiogenesis, and 
tumor invasion (32–35). IL-1β and EGF act synergistically and 
induce cell migration and invasion through increased expression 
and activity of MMPs (36).
Interleukin-8 and G-CSF are powerful stimulators of neutro-
phil generation, mobilization, activation, and survival (37–39). 
IL-8 induces multiple intracellular signaling pathways known to 
be constitutively active in tumor cells, neutrophils, and TAMs. 
IL-8 is also associated with angiogenesis, proliferation, tumor 
cell migration, and tumor progression to aggressive stages of the 
disease (37, 40–44). Fridlender and colleagues have postulated 
that neutrophils may have N1/N2 polarization states that mirror 
the M1/M2 phenotypes reported for macrophages; in which, 
the N2 and M2 types have pro-tumor activities (45). In a mouse 
model of BrC, Swierczak and colleagues found that blocking 
the CSF-1 (M-CSF)/CSF-1R interaction to prevent recruitment 
of circulating monocytes and M2 polarization increased the 
serum levels of G-CSF, leading to increased neutrophils in the 
primary tumor, and increased lung metastasis. When a G-CSF 
receptor antagonistic antibody was administered, it reversed the 
infiltration of neutrophils and reduced lung metastasis (46). In 
future studies, it will be interesting to further explore the possible 
collaboration between tumor cells, monocytes/macrophages and 
neutrophils; and to assess the capacity of these interactions to 
suppress T cell function.
In our model, cytokines that inhibit tumorigenesis were found 
to be suppressed. IL-12p70 and IFN-α2 were downregulated in 
all PC and commercial BrC cells. GM-CSF was downregulated 
in six PC, and in MCF-7 and T47D non-aggressive cells. These 
cytokines are known to have strong anti-tumor activity and 
are being used as immunoadjuvants in anti-cancer vaccines. 
Recombinant human INF-α2b is part of an US Food and Drug 
Administration (FDA)-approved anti-tumor therapy (47–49). 
FigUre 7 | Working model. Tumor cells coerce monocytes/macrophages 
to fulfill activities more attune with tumor grow. MCP-1, G-SCF, and RANTES 
may be critical components of the message send by tumor cells. Monocytes/
macrophages respond helping to establish an inflammatory 
microenvironment rich in cytokines with pro-tumor activities such as 
interleukin (IL)-1β and IL-8, which paradoxically may be immunosuppressive 
of cytotoxic T cell function, since it is high in the previously mentioned 
cytokines plus GM-CSF and low in INF-α2 and IL-12p70. This inflammatory 
microenvironment is also enriched of metalloproteinases (MMPs) that 
promote the degradation of ECM. Altogether, this microenvironment may 
facilitate the epithelial to mesenchymal transition (EMT), which facilitates 
invasion and probably metastasis and chemoresistance. The most aggressive 
tumor cells seem to be more efficient to establish this pro-tumoral 
microenvironment that further boosts tumor aggressiveness, thus creating a 
positive feedback loop.
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IL-12p70 promotes the expansion and activation of cytotoxic 
CD8 T cells (50, 51) and has been used to stimulate immune 
anti-tumor activity in animal models (52). IL-12p70 has also been 
administered in clinical trials to increase the anti-tumor activity 
of anti-cancer vaccines (53–56). GM-CSF, a potent chemoattract-
ant of neutrophils, monocytes, and lymphocytes (57), has also 
been used as adjuvant therapy in cancer vaccines. Interestingly, it 
was found that high GM-CSF doses favored pro-tumor activities, 
and low doses were an effective immune adjuvant (58).
One of the main mechanisms promoting tumor cell invasion 
and metastasis is the EMT (59). EMT-promoted cell invasion 
requires ECM degradation to facilitate cell migration. Mounting 
evidence support that both IL-1β and IL-8 promote EMT in 
tumor cells (28, 35, 60–63) and induce tumor cells, and other 
stromal cells, to secrete MMPs (61, 64–69). MMPs play a key role 
in the malignant progression of cancer. Their activity degrades 
and remodels the ECM, and liberates trapped cytokines and 
growth factor precursors (70–73). In this study, we observed 
that the levels of MMP-1, MMP-2, and MMP-10 significantly 
increased in co-cultures of tumor cells/monocytes, and we have 
previously shown that this correlates with increased collagen 
degradation (14). High levels of expression of MMP-1 have 
been associated with tumor growth, invasion and metastasis 
(74, 75), and MMP-1 levels have been proposed as a marker of 
poor prognosis in colorectal, breast, and lung cancers (74, 76, 
77). MMP-1 has been associated with metastasis to brain in a 
BrC xenograft model (75). High levels of MMP-2 also correlate 
with tumor aggressiveness in various types of cancers (78–80). 
MMP-10 also catalyzes the conversion of pro-MMP-1 into its 
active form. MMP-10 expression has been associated with inva-
sion and metastasis of pancreatic, cervical, bladder, colorectal, 
gastric, lung, and breast cancers (81–85).
In summary, cancer aggressiveness is strongly influenced by 
how tumor cells communicate with other cells within the tumor 
stroma. Considering that the intra- and inter-tumoral genetic 
heterogeneity have hampered the design of efficient therapeutic 
strategies, it is possible that the mechanisms that the tumor 
uses to communicate with its stroma are more limited and may 
provide better prognostic and therapeutic targets. Of interest is 
that the profile of cytokines enriched in tumor cells co-cultured 
with monocytes better corresponds to the one aided by M1 
macrophages, rather than M2 macrophages. This is in agreement 
with our recent study in which we observed a mix of M1 and 
M2 types enriched upon monocytes co-culture with tumor cells 
(15). Interestingly, based on the morphology and behavior in 
co-culture with monocytes, the primary tumor cells more closely 
resemble aggressive cell lines. However, most of the patients were 
classified in clinical stage II and tumor grade II. In agreement, 
four PC exhibited EMT and invasive properties (Figure S1 in 
Supplementary Material) (86). We were not able to follow up the 
patients from which the primary tumor cells were expanded. In 
future studies it would be very interesting to analyze the nature 
of the tumor cells in culture (2D and 3D morphology, growth in 
mesenchymal medium), and their ability to instruct monocytes/
macrophages to establish an inflammatory microenvironment 
rich in cytokines with pro-tumoral functions, and to compare 
these data with clinical staging and patient survival.
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